Transparent decision making is essential.
At least three of the many companies making covid-19 vaccines have past criminal and civil settlements costing them billions of dollars
The BMJ supports vaccination policies based on sound evidence.
The same applies to treatments for covid-19
Data must be available when trial results are announced, published, or used to justify regulatory decisions.
There is no place for wholesale exemptions from good practice during a pandemic.
Covid-19 vaccines and treatments: we must have raw data, now
https://www.bmj.com/content/376/bmj.o102
Data should be fully and immediately available for public scrutiny
Dr John Campbell - Data, we want it all
https://youtu.be/YDxkloJ-4kEPfizer has indicated that it will not begin entertaining requests for trial data until May 2025, (NCT04368728).
Moderna data may be available … with publication of the final study results in 2022
Datasets will be available upon request and subject to review once the trial is complete
Estimated primary completion date 27 October 2022 (NCT04470427).
Regeneron’s phase III trial of monoclonal antibody therapy REGEN-COV
Participant level data will not be made available to others EMU)
Should the drug be approved, sharing will be considered